PET Infusion System Has Workflow Enhancements Upgrade

A next-generation positron emission tomography (PET) infusion system features a new design that is 38% smaller, power-driven, and includes enhancements to technologists' workflow.

Medrad, Inc. (Warrendale, PA, USA), a business of Bayer HealthCare (Leverkusen, Germany), has announced the launch of the next generation Intego infusion system. The new Intego will be on display at the annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, 2011, in San Antonio (TX, USA).

The Intego PET infusion system, originally launched in 2008, remains the only US Food and Drug Administration (FDA)-cleared device for automated, controlled infusion of F18-fluorodeoxyglucose (FDG) and F18-NaF, the most common PET diagnostic imaging agents used in oncology. Intego PET infusion systems have been sold worldwide.

"The new Intego demonstrates our commitment to continued innovation and leadership in molecular imaging. Now, in an even smaller, more mobile design, Intego can significantly reduce radiation exposure and improve patient care. This is just another way we are driving smarter, safer, simpler PET," said Doug Descalzi, executive director, Medrad Molecular Imaging.

Related Links:
Medrad